Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat.
Tiagabine is a new anticonvulsant drug that blocks the uptake of GABA, prolonging the action of this inhibitory transmitter. In the present study the effects of systemically administered tiagabine [30 mg/kg, ip (ED50)] were examined on audiogenic seizure (AGS) severity and neuronal firing in the inferior colliculus (IC) in the freely moving genetically epilepsy-prone rat (GEPR-9). The IC is known to be critical to AGS initiation. The effects of focal microinjection of tiagabine into the IC were also examined. Bilateral focal microinjection of tiagabine into the IC significantly reduced seizure severity in the GEPR-9. Systemically administered tiagabine also produced a significant reduction in seizure severity in the GEPR-9. Tiagabine produced a reduction in IC (central nucleus) neuronal firing, which was significant only at high acoustic intensities (90-105 dB), concomitant with the considerable reduction in seizure severity. These data are consistent with enhancement by tiagabine of gamma-aminobutyric acid (GABA)-mediated inhibition in IC, which is most prominent at high acoustic intensities. The time course of the reduction in neuronal firing of IC neurons paralleled the reduction in seizure severity. Previous studies have shown that two forms of GABA-mediated inhibition (intensity-induced and offset inhibition) in IC neurons are most prominent at high stimulus intensities, which are required to induce AGS. The blockade of GABA uptake by tiagabine may act to inhibit audiogenic seizures, in part, by intensifying these naturally occurring forms of acoustically evoked inhibition in inferior colliculus neurons.
Faingold
C L
CL
Department of Pharmacology, Southern Illinois University School of Medicine, Springfield 62794.
Randall
M E
ME
Anderson
C A
CA
D000161:Acoustic Stimulation; D000818:Animals; D001931:Brain Mapping; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000235:genetics / Q000503:physiopathology*; D005260:Female; D018756:GABA Antagonists / Q000494:pharmacology*; D007245:Inferior Colliculi / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D008297:Male; D008845:Microinjections; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D009557:Nipecotic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011922:Rats, Mutant Strains; D012640:Seizures / Q000503:physiopathology / Q000517:prevention & control; D000078308:Tiagabine; D013997:Time Factors
D018756:GABA Antagonists; D009557:Nipecotic Acids; D000078308:Tiagabine